尿液蛋白质组生物标志物动态与IgA肾病疾病进展
本研究在活检确诊的IgA肾病患者中,于基线(IgAN237-1,n=103)和随访(IgAN237-2,n=89)时用毛细管电泳-质谱分析尿液,按IgAN237分类器(≤0.38为非进展者,>0.38为进展者)分组。结果显示IgAN237与eGFR斜率负相关,基线进展者是eGFR180天斜率的独立预测因子。结论认为IgAN237分类器可作为疾病动态过程中后期风险分层工具,可能指导个体化管理。
要点
- IgAN237-1与IgAN237-2值无显著差异且相关(rho=0.44,P<.001)。
- 进展者±180天eGFR斜率较非进展者更差(IgAN237-1中位-5.98 vs -1.22 mL/min/1.73 m2/年,P<.001)。
- 基线IgAN237进展者/非进展者是eGFR180天斜率的独立预测因子(P=.001)。
核心结论
- 尿液IgAN237分类器可作为IgA肾病动态病程后期风险分层工具,可能以个体化方式指导患者管理。
研究设计与样本
- 对活检确诊的IgA肾病患者,在基线(IgAN237-1,n=103)和随访(IgAN237-2,n=89)时用毛细管电泳-质谱分析尿液,按IgAN237≤0.38和>0.38分为非进展者和进展者,计算eGFR和尿白蛋白-肌酐比值斜率。
主要发现
- 活检时中位年龄44岁,活检至IgAN237-1间隔65个月,IgAN237-1至IgAN237-2间隔258天(四分位距71-531)。
- IgAN237-1和IgAN237-2值无显著差异且相关(rho=0.44,P<.001)。
- 基于IgAN237-1和IgAN237-2,分别有28%和26%的患者为进展者。
- IgAN237与慢性eGFR斜率负相关(评分-1:rho=-0.278,P=.02;评分-2:rho=-0.409,P=.002),与±180天eGFR斜率负相关(rho=-0.31,P=.009;rho=-0.439,P=.001)。
- 进展者±180天eGFR斜率较非进展者更差(IgAN237-1中位-5.98 vs -1.22 mL/min/1.73 m2/年,P<.001;IgAN237-2中位-3.02 vs 1.08 mL/min/1.73 m2/年,P=.0047)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunoglobulin A nephropathy (IgAN) frequently leads to kidney failure. The urinary proteomics-based classifier IgAN237 may predict disease progression at the time of kidney biopsy. We studied whether IgAN237 also predicts progression later in the course of IgAN. METHODS: Urine from patients with biopsy-proven IgAN was analyzed using capillary electrophoresis-mass spectrometry at baseline (IgAN237-1, n = 103) and at follow-up (IgAN237-2, n = 89). Patients were categorized as "non-progressors" (IgAN237 ≤0.38) and "progressors" (IgAN237 >0.38). Estimated glomerular filtration rate (eGFR) and urinary albumin-creatinine ratio slopes were calculated. RESULTS: Median age at biopsy was 44 years, interval between biopsy and IgAN237-1 was 65 months and interval between IgAN237-1 and IgAN237-2 was 258 days (interquartile range 71-531). IgAN237-1 and IgAN237-2 values did not differ significantly and were correlated (rho = 0.44, P < .001). Twenty-eight percent and 26% of patients were progressors based on IgAN237-1 and IgAN237-2, respectively. IgAN237 inversely correlated with chronic eGFR slopes (rho = -0.278, P = .02 for score-1; rho = -0.409, P = .002 for score-2) and with ±180 days eGFR slopes (rho = -0.31, P = .009 and rho = -0.439, P = .001, respectively). The ±180 days eGFR slopes were worse for progressors than for non-progressors (median -5.98 versus -1.22 mL/min/1.73 m2 per year for IgAN237-1, P < .001; -3.02 vs 1.08 mL/min/1.73 m2 per year for IgAN237-2, P = .0047). In multiple regression analysis baseline progressor/non-progressor according to IgAN237 was an independent predictor of eGFR180days-slope (P = .001). CONCLUSION: The urinary IgAN237 classifier represents a risk stratification tool in IgAN also later in the course of the dynamic disease. It may guide patient management in an individualized manner.
引用
- Peters B, Beige J, Siwy J, et al. Dynamics of urine proteomics biomarker and disease progression in patients with IgA nephropathy. Nephrol Dial Transplant. 2023. PMID: 37349951. doi:10.1093/ndt/gfad125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。